In vivo CAR-T
Instead of engineering T cells in a factory, an injection reprograms them inside the patient's body.
Targeted lipid nanoparticles (Capstan/AbbVie CPTX2309, Orna) or lentiviral vectors (Umoja, Interius INT2104) deliver CAR-encoding mRNA or DNA to T cells in vivo. First-in-human data (2025-26) show B-cell depletion and responses without lymphodepletion or manufacturing wait. Transient mRNA expression may reduce long-term risk. Capstan was acquired by AbbVie for up to $2.1B in 2025, signalling the field's expectations.
How it works
CD8- or CD3-targeted LNP or viral vector transduces circulating T cells to express a CAR in situ.
- Off-the-shelf, redosable, no lymphodepletion
- Potentially 10x cheaper
- Transduction efficiency and durability
- Off-target transfection
- Very early
Latest papers
topQuery for this technology: (TITLE:"in vivo CAR T" OR ABSTRACT:"in vivo CAR T" OR TITLE:"in vivo CAR-T" OR ABSTRACT:"in vivo CAR-T" OR TITLE:"in vivo chimeric antigen receptor" OR ABSTRACT:"in vivo chimeric antigen receptor"). Results are unfiltered search hits about In vivo CAR-T, not a curated reading list.